Endoscopic Sleeve Gastroplasty After Solid Organ Transplantation: First Reported Case Worldwide in a Kidney Transplant Recipient Authors: Ehab Abufarhaneh, Ayed Alqahtani, Barham Abu Dayyeh, Ahmed Adel Amin, Ahmed Nazmi, Dieter Broering Published: 2026 ABSTRACT Obesity adversely affects graft and cardiovascular outcomes in kidney transplant recipients, with limited effective therapies. Endoscopic sleeve gastroplasty (ESG) is established for obesity but not well studied post-transplant. We report ESG in a 33-year-old kidney transplant recipient with class III obesity. A structured search (PubMed, Embase, Scopus; January 2025) found no prior cases. ESG was completed without complications. At 6 months, meaningful weight loss and metabolic improvement occurred, with stable graft function. Semen parameters improved, without proven causality. ESG appears feasible and well tolerated in a selected patient. Safety cannot be established. Larger studies are needed. INTRODUCTION Obesity is a growing global health concern and is particularly prevalent among solid organ transplant recipients, including those with kidney transplants.1 Post-transplant obesity is associated with increased risks of hypertension, diabetes, cardiovascular disease, and reduced graft longevity.2 Managing obesity in this population is challenging due to the complex interplay of immunosuppressive therapy, comorbidities, and the risks associated with traditional weight loss interventions. Bariatric surgery has been considered a viable option for severely obese transplant recipients; however, concerns regarding surgical risks, impaired wound healing, immunosuppression, and potential drug absorption issues limit its widespread use.3 Consequently, there is increasing interest in less invasive endoscopic approaches such as endoscopic sleeve gastroplasty (ESG), which mimics surgical sleeve gastrectomy while avoiding resection and reducing procedural morbidity.4 ESG has demonstrated promising results in achieving sustained weight loss and improving metabolic outcomes in nontransplant populations.5,6 However, its safety and effectiveness in transplant recipients remain unclear. To address this gap, we conducted a structured literature search (PubMed, Embase, and Scopus; January 2025) using terms related to ESG and transplantation, which identified no prior reports in kidney transplant recipients. We therefore present what is, to the best of our knowledge, the first reported case of ESG in a kidney transplant recipient, focusing on feasibility, short-term outcomes, and transplant-specific considerations. CASE REPORT A 33-year-old man with a history of living-related kidney transplantation in March 2023 for focal segmental glomerulosclerosis presented for management of morbid obesity, nonalcoholic steatohepatitis, and infertility. At presentation, his weight was 123 kg with a body mass index (BMI) of 41.4 kg/m2. After limited success with conventional weight-loss strategies, the patient elected to undergo ESG after informed discussion. His BMI immediately before the procedure was 41.1 kg/m2. ESG was performed under general anesthesia on March 28, 2025. Diagnostic gastroscopy revealed no contraindications. Three sutures (4–5 stitches each) were placed successfully without complications. Postprocedural assessment confirmed intact suture lines without bleeding. The patient remained hemodynamically stable throughout. At 6 months, body weight decreased from 123 kg to 108 kg, with BMI reduction from 41 to 36.1 kg/m2, representing clinically meaningful weight loss. This was accompanied by improvement in obesity-related comorbidities, while graft function remained stable throughout follow-up. Semen analysis demonstrated improvements in total sperm count, concentration, motility, and morphology, with a shift from asthenoteratozoospermia to normozoospermia. Renal function remained stable with no evidence of graft dysfunction. The immunosuppressive regimen included prednisone, mycophenolate mofetil (MMF), and tacrolimus. MMF was withheld for 10 days before and after the procedure to reduce infection risk and support mucosal healing. Tacrolimus levels were maintained at ∼9 ng/mL, and prednisone was temporarily increased periprocedurally and tapered thereafter. MMF was reintroduced at a reduced dose before titration to baseline. The patient underwent close clinical and laboratory monitoring throughout. DISCUSSION This report describes, to the best of our knowledge, the first use of ESG in a kidney transplant recipient and demonstrates that the procedure is technically feasible and was well tolerated in this carefully selected case. Meaningful weight loss was achieved with preserved graft function over 6 months. However, given the single-case design and short follow-up, these findings should be interpreted cautiously. Obesity after transplantation is associated with increased cardiovascular risk, metabolic complications, and reduced graft survival.1,2 The degree of weight loss observed aligns with outcomes reported in nontransplant ESG cohorts.6 However, extrapolation to transplant recipients is limited in the absence of dedicated studies. Compared with bariatric surgery, ESG offers potential advantages in transplant populations. Surgical approaches, although effective, are associated with risks of perioperative complications, impaired wound healing, and altered immunosuppressant absorption.3,7 ESG preserves gastrointestinal anatomy and avoids resection, with favorable safety profiles reported in nontransplant populations.6,7 Nevertheless, the absence of complications in a single patient does not establish safety, particularly in immunosuppressed individuals who may be at risk of delayed infection, nutritional deficiencies, or altered drug pharmacokinetics. Periprocedural immunosuppression management is a key consideration. In this case, temporary MMF withdrawal was used to reduce infection risk and support mucosal healing, balanced against rejection risk through maintenance of tacrolimus levels and corticosteroid adjustment. While successful here, no standardized protocol exists, and management should be individualized within a multidisciplinary transplant-endoscopy framework. Existing guidance suggests that short-term immunosuppression modification may be safely performed in selected contexts,8 but further evidence is needed for endoscopic bariatric procedures. Improvement in semen parameters was also observed. Obesity negatively affects male fertility through endocrine and inflammatory mechanisms,9 and weight loss has been associated with improved sperm parameters.5 However, causality cannot be established in a single case. Alternative explanations, including post-transplant recovery and immunosuppression stabilization, should be considered. This finding should therefore be interpreted as an associated observation. Careful patient selection is critical. Suitable candidates may include patients with stable graft function, no recent rejection, stable immunosuppression, and adequate time from transplantation (e.g., ≥12 months). Evaluation should occur within a multidisciplinary team, and procedures should be performed in specialized centers with expertise in both transplant medicine and advanced endoscopy (Figures 1–3). (A) Weight trajectory of the patient from February to October 2025, demonstrating progressive weight reduction following endoscopic sleeve gastroplasty (vertical dashed line indicates date of intervention, March 28, 2025). (B) Body mass index over the same period, showing a parallel decline. Both parameters demonstrated clinically meaningful improvements within 6 months postprocedure while maintaining stable graft function. Comparison of semen analysis parameters before and after endoscopic sleeve gastroplasty. Improvements were observed in total sperm count, sperm concentration, progressive motility, and morphology at 6 months postprocedure. Diagnosis shifted from asthenoteratozoospermia (2024) to normozoospermia (2025). acrosomal def.: acrosomal deficiency; amorphous, amorphous head forms; bent forms, bent tail forms; Prog. motility, progressive motility; Sperm Conc., sperm concentration; total motile, total motile sperm; vacuolated, vacuolated head forms. Serum creatinine trend from September 2023 to September 2025, with vertical dashed line marking the date of endoscopic sleeve gastroplasty (March 28, 2025). Renal graft function remained stable throughout follow-up, with no evidence of postprocedural deterioration. This case highlights important areas for future research, including long-term graft outcomes, durability of weight loss under immunosuppression, drug absorption, and nutritional status. Current guidelines emphasize lifestyle interventions and consider bariatric surgery in selected patients, with limited guidance on endoscopic therapies.8 ESG may represent a feasible, minimally invasive alternative in selected cases but should currently be considered investigational. This case represents, to the best of our knowledge, the first reported use of ESG in a kidney transplant recipient and demonstrates that the procedure is technically feasible and well tolerated in a carefully selected patient, with meaningful short-term weight loss and preserved graft function. However, given the single-case design and limited follow-up, no conclusions regarding safety or efficacy can be established. ESG in transplant recipients should therefore be considered investigational. Larger prospective studies are required to evaluate long-term outcomes, including graft function, immunosuppressant pharmacokinetics, nutritional status, and durability of weight loss, and to define appropriate patient selection and management strategies. DISCLOSURES Author contributions: E. Abufarhaneh and AA Amin performed the data collection, analysis and interpretation. A. Alqahtani, E. Abufarhaneh, and AA Amin and actively managed the patient before and after the procedure and performed the endoscopic procedure. A. Nazmi managed the patient from the renal transplant aspect, before and after the procedure. E. Abufarhaneh and AA Amin wrote the original manuscript. A. Alqahtani, BA Dayyeh and D. Broering were major contributors to the writing and editing of the manuscript. All the authors read and approved the final manuscript. E. Abufarhaneh is the article guarantor. Financial disclosure: None to report. Informed consent was obtained for this case report. Declaration of AI use: During preparation of this manuscript, the authors used (GPT-5 Thinking; OpenAI, San Francisco, CA; accessed September 17, 2025) to assist with language editing and style harmonization based on the authors' outlines. The authors critically reviewed, edited, and approved all content and take full responsibility for the integrity and accuracy of the work. The AI system is not listed as an author and did not generate, analyze, or interpret data, nor did it select or verify references. No AI-generated images or figures were used. No identifiable or nonpublic patient information was entered into the tool, and use complied with institutional, ethical, and publisher policies. Ethics and consent: the patient has provided an informed consent for publication of this case.